Scarica l'app Stockscreener
3.0401
1.93%
-0.0699
Precedente Chiudi:
$3.11
Aprire:
$3.09
Volume 24 ore:
103.83K
Relative Volume:
0.21
Capitalizzazione di mercato:
$191.46M
Reddito:
$163.78M
Utile/perdita netta:
$25.88M
Rapporto P/E:
4.6771
EPS:
0.65
Flusso di cassa netto:
$-28.66M
1 W Prestazione:
+1.67%
1M Prestazione:
+11.31%
6M Prestazione:
-46.21%
1 anno Prestazione:
-61.20%
Intervallo 1D:
$3.00
$3.09
Intervallo di 1 settimana:
$2.83
$3.17
Portata 52W:
$2.645
$9.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Nome
Voyager Therapeutics Inc
Settore
Industria
Telefono
857-259-5340
Indirizzo
75 HAYDEN AVENUE, LEXINGTON, MA
Confronta VYGR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.045 | 191.46M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.90 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
535.57 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.74 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.42 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Iniziato | Citigroup | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-10-16 | Iniziato | Leerink Partners | Outperform |
| 2024-03-26 | Iniziato | Guggenheim | Buy |
| 2024-03-19 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-07 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Iniziato | Truist | Buy |
| 2023-03-10 | Iniziato | Oppenheimer | Outperform |
| 2021-10-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Downgrade | BTIG Research | Buy → Neutral |
| 2021-02-03 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Iniziato | The Benchmark Company | Buy |
| 2020-02-06 | Iniziato | Oppenheimer | Outperform |
| 2018-11-15 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-09-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-02-02 | Iniziato | Morgan Stanley | Overweight |
| 2017-11-28 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2017-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-23 | Reiterato | Stifel | Buy |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-28 | Ripresa | Stifel | Buy |
Mostra tutto
Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie
Financial Comparison: Prime Medicine (NYSE:PRME) & Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics at H.C. Wainwright: Genetic Innovation in Focus By Investing.com - Investing.com Canada
Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspecti - GuruFocus
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | VYGR Stock News - GuruFocus
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire
Millennium Management LLC Sells 60,935 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Squarepoint Ops LLC Decreases Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade) - Seeking Alpha
Voyager Therapeutics Approves Stock Plans at Annual Meeting - TipRanks
BNP Paribas Financial Markets Sells 43,210 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Holdings Lowered by ProShare Advisors LLC - Defense World
Deutsche Bank AG Cuts Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Jane Street Group LLC - Defense World
Voyager Therapeutics stock plunges to 52-week low of $2.71 By Investing.com - Investing.com South Africa
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates - MSN
Voyager Therapeutics stock plunges to 52-week low of $2.71 - Investing.com
It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year - simplywall.st
Northern Trust Corp Raises Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
With 46% ownership, Voyager Therapeutics, Inc. (NASDAQ:VYGR) has piqued the interest of institutional investors - Yahoo Finance
Cubist Systematic Strategies LLC Buys New Shares in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Tower Research Capital LLC TRC Increases Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Brokerages - Defense World
Voyager Therapeutics (VYGR) Showcases Breakthrough in Gene Thera - GuruFocus
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain - GlobeNewswire
Revolutionary Brain Drug Delivery: Voyager's New Gene Therapy Shows 400x Improvement in Landmark Research - Stock Titan
Voyager reports breakthrough in brain drug delivery - Investing.com
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Voyager Therapeutics (VYGR) and Privia Health Group (PRVA) - The Globe and Mail
Q2 EPS Forecast for Voyager Therapeutics Reduced by Analyst - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Position Increased by Dimensional Fund Advisors LP - Defense World
FY2025 EPS Estimates for VYGR Increased by Cantor Fitzgerald - Defense World
Leerink Partnrs Has Negative Outlook of VYGR Q2 Earnings - Defense World
Q2 EPS Estimates for Voyager Therapeutics Lifted by Wedbush - Defense World
Voyager Therapeutics Reports Q1 2025 Financial Results - TipRanks
Barclays PLC Buys 10,328 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Analysts Have Conflicting Sentiments on These Healthcare Companies: Omnicell (OMCL), Voyager Therapeutics (VYGR) and Masimo (MASI) - The Globe and Mail
Voyager Therapeutics Inc earnings missed by $0.08, revenue fell short of estimates - Investing.com India
Raymond James Financial Inc. Takes $746,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics: Q1 Earnings Snapshot - Connecticut Post
Voyager Reports First Quarter 2025 Financial and Operating Results - The Manila Times
Voyager Therapeutics Q1 2025 Financial and Operating Results - TradingView
Voyager Therapeutics, Inc. SEC 10-Q Report - TradingView
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Renaissance Technologies LLC - Defense World
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer - Stock Titan
BlackRock, Inc. Reduces Stake in Voyager Therapeutics Inc - GuruFocus
Voyager Therapeutics Inc Azioni (VYGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Voyager Therapeutics Inc Azioni (VYGR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO |
Apr 02 '25 |
Sale |
3.43 |
10,885 |
37,336 |
430,931 |
0.17%
1.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):